Mar 21, 2013, 05.01 PM | Source: CNBC-TV18
Sudarshan Sukhani of s2analytics.com advised holding GlaxoSmithKline Pharmaceuticals.
Sudarshan Sukhani (more)
Technical Analyst, s2analytics.com | Capital Expertise: Equity - Technical
Sukhani told CNBC-TV18, “It is a no brainer, stick with GlaxoSmithKline Pharmaceuticals , not because it is a defensive or because it is making money but because the target for this stock on the basis of charts is Rs 2500-2600 and you have nothing to loose.”
“Suppose it goes 200 points down, that does not mean anything. The chances are it will rally back again. So you are using your own profits to cover yourself and hopefully you should get much more,” Sukhani added.
Witty, a 31-year company veteran, has been under f
GlaxoSmithKline Pharmaceuticals' fourth quarter ne
GSK India's managing director, Hasit Joshipura, sp
PINC Research is bearish on GlaxoSmithKline Pharma
Motilal Oswal is bullish on GlaxoSmithKline Pharma
According to Sudarshan Sukhani of s2analytics.com,
Sudarshan Sukhani of s2analytics.com recommends se
Facing protest, the government today kept in abeya